Article
Emerging Developments in ETS-Positive Prostate Cancer Therapy
12 Dec 2022
Abstract excerpt
Prostate cancer is a global health concern, which has a low survival rate in its advanced stages. Even though second-generation androgen receptor-axis inhibitors serve as the mainstay treatment options, utmost of the metastatic cases progress into castration-resistant prostate cancer after their initial treatment response with poor prognostic outcomes. Hence, there is a dire need to develop effective inhibitors...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
